Longer-term RBC transfusion reduction in the phase III MEDALIST study of luspatercept in patients (pts) with lower-risk MDS with ring sideroblasts (RS).

被引：0
|
作者：
Komrokji, Rami S.
Sekeres, Mikkael A.
Zeidan, Amer Methqal
Fenaux, Pierre
List, Alan F.
Dezern, Amy Elizabeth
Greenberg, Peter L.
Savona, Michael R.
Jurcic, Joseph G.
Verma, Amit
Mufti, Ghulam J.
Buckstein, Rena
Santini, Valeria
Laadem, Abderrahmane
Ito, Rodrigo
Zhang, Jennie
Louis, Chrystal Ursula
Linde, Peter G.
Garcia-Manero, Guillermo
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[2] Cleveland Clin, Dept Hematol & Med Oncol, Cleveland, OH 44106 USA
[3] Yale Univ, Yale Sch Med, Dept Internal Med, New Haven, CT USA
[4] Yale Univ, Yale Canc Ctr, Dept Internal Med, New Haven, CT USA
[5] Univ Paris 07, Serv Hematol Seniors, Hop St Louis, Paris, France
[6] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[7] Stanford Univ, Canc Ctr, Stanford, CA 94305 USA
[8] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA
[9] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Div Hematol Oncol, Med Ctr, New York, NY USA
[10] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Oncol, Bronx, NY 10467 USA
[11] Kings Coll London, Dept Haematooncol, London, England
[12] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada
[13] Univ Florence, Azienda Osped Univ AOU Careggi, MDS Unit, Florence, Italy
[14] Bristol Myers Squibb, Summit, NJ USA
[15] Acceleron Pharma, Cambridge, MA USA
[16] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7518
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Assessment of longer-term efficacy, safety, and haematological improvement in the phase 3, randomised, double-blind, placebo-controlled MEDALIST trial of luspatercept to treat anaemia in patients with lower-risk myelodysplastic syndromes with ring sideroblasts who require red blood cell transfusions
    Mufti, G. J.
    Vyas, P.
    Buckstein, R.
    Santini, V.
    Diez-Campelo, M.
    Finelli, C.
    Ilhan, O.
    Sekeres, M. A.
    Komrokji, S.
    Zeidan, A. M.
    Verma, A.
    Laadem, A.
    Linde, G.
    List, A. F.
    Platzbecker, U.
    Garcia-Manero, G.
    Fenaux, P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 140 - 140
  • [22] CHANGES IN TRANSFUSION BURDEN (TB), HEMOGLOBIN (HB), SERUM FERRITIN (SF), AND IRON CHELATION THERAPY (ICT) USE IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES WITH RING SIDEROBLASTS TREATED WITH LUSPATERCEPT FROM THE MEDALIST STUDY
    Platzbecker, U.
    Garcia-Manero, G.
    Komrokji, R. S.
    Tang, D.
    Ito, R.
    Fabre, S.
    Zhang, G.
    Ha, X.
    Mantovani, E.
    Miteva, D.
    Zinger, T.
    Fenaux, P.
    VALUE IN HEALTH, 2021, 24 : S19 - S19
  • [23] A PHASE 2 STUDY OF AZACITIDINE AND EPOETIN-BETA IN UNTREATED RBC-TRANSFUSION DEPENDENT LOWER-RISK MDS PATIENTS
    Sanz, G.
    de Paz, R.
    Bernal, T.
    Bargay, J.
    Montesinos, P.
    Diez-Campelo, M.
    del Canizo, C.
    LEUKEMIA RESEARCH, 2015, 39 : S61 - S61
  • [24] LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS): LONG-TERM RESULTS FROM PHASE 2 PACE-MDS STUDY
    Giagounidis, A.
    Germing, U.
    Goetze, K.
    Kiewe, P.
    Wolff, T.
    Mayer, K.
    Chromik, J.
    Radsak, M.
    Wilson, D.
    Zhang, X.
    Laadem, A.
    Sherman, M. L.
    Attie, K. M.
    Linde, P. G.
    Platzbecker, U.
    HAEMATOLOGICA, 2017, 102 : 264 - 264
  • [25] Long-Term Efficacy and Safety of Luspatercept in Lower-Risk Myelodysplastic Syndromes (MDS): Phase 2 PACE-MDS Study
    Platzbecker, Uwe
    Kiewe, Philipp
    Germing, Ulrich
    Goetze, Katharina
    Mayer, Karin
    Radsak, Markus
    Wolff, Thomas
    Chromik, Joerg
    Reynolds, Joseph
    Barron, Carolyn
    Zhang, Xiaosha
    Laadem, Abderrahmane
    Attie, Kenneth
    Giagounidis, Aristoteles
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S319 - S320
  • [26] Benefit of Continuing Luspatercept Therapy in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Who Did Not Achieve Red Blood Cell Transfusion Independence (RBC-TI) by Week 25 in the MEDALIST Study
    Platzbecker, Uwe
    Germing, Ulrich
    Fenaux, Pierre
    Buckstein, Rena
    Santini, Valeria
    Diez-Campelo, Maria
    Tang, Derek
    Ito, Rodrigo
    Fabre, Shannon
    Mantovani, Emily
    Zhang, George
    Ha, Xianwei
    Miteva, Dimana
    Hughes, Christina
    Khan, Wasiulla
    Komrokji, Rami S.
    Garcia-Manero, Guillermo
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 142 - 143
  • [27] Multiple Episodes of Transfusion Independence with Luspatercept Treatment and the Impact of Dose Escalation in Patients with Lower-Risk Myelodysplastic Syndromes from the MEDALIST Study
    Platzbecker, Uwe
    Santini, Valeria
    Komrokji, Rami S.
    Zeidan, Amer M.
    Garcia-Manero, Guillermo
    Buckstein, Rena
    Oliva, Esther Natalie
    Pozharskaya, Veronika
    Ha, Xianwei
    Nadal, Jose Alberto
    Miteva, Dimana
    Fenaux, Pierre
    BLOOD, 2022, 140 : 6971 - 6973
  • [28] Mutational Profile and Analysis of Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Luspatercept: Phase 2 PACE-MDS Study
    Platzbecker, Uwe
    Kiewe, Philipp
    Germing, Ulrich
    Gotze, Katharina S.
    Mayer, Karin
    Radsak, Markus P.
    Wolff, Thomas
    Chromik, Joerg
    Wilson, Dawn
    Zhang, Xiaosha
    Rovaldi, Chris
    Laadem, Abderrahmane
    Sherman, Matthew Leigh
    Attie, Kenneth Morris
    Reynolds, Joseph
    Linde, Peter Guest
    Giagounidis, Aristoteles
    BLOOD, 2017, 130
  • [29] Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts
    Uwe Platzbecker
    Valeria Santini
    Rami S. Komrokji
    Amer M. Zeidan
    Guillermo Garcia-Manero
    Rena Buckstein
    Dimana Miteva
    Karen Keeperman
    Natalia Holot
    Jose Alberto Nadal
    Yinzhi Lai
    Sadanand Vodala
    Barbara Rosettani
    Ana Carolina Giuseppi
    Aylin Yucel
    Pierre Fenaux
    Leukemia, 2023, 37 : 2314 - 2318
  • [30] Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts
    Platzbecker, Uwe
    Santini, Valeria
    Komrokji, Rami S.
    Zeidan, Amer M.
    Garcia-Manero, Guillermo
    Buckstein, Rena
    Miteva, Dimana
    Keeperman, Karen
    Holot, Natalia
    Nadal, Jose Alberto
    Lai, Yinzhi
    Vodala, Sadanand
    Rosettani, Barbara
    Giuseppi, Ana Carolina
    Yucel, Aylin
    Fenaux, Pierre
    LEUKEMIA, 2023, 37 (11) : 2314 - 2318
12345